BIIB019 (Daclizumab)

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Relapsing-Remitting Multiple Sclerosis

Conditions

Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis

Trial Timeline

Feb 15, 2013 → Sep 24, 2018

NCT ID

NCT01797965

About BIIB019 (Daclizumab)

BIIB019 (Daclizumab) is a phase 3 stage product being developed by AbbVie for Relapsing-Remitting Multiple Sclerosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01797965. Target conditions include Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01797965	Phase 3	Terminated	Feb 15, 2013	Sep 24, 2018	Relapsing-Remitting Multiple Sclerosis

Competing Products

20 competing products in Relapsing-Remitting Multiple Sclerosis

See all competitors

Product	Company	Stage	Hype Score
CT-P53 + US-Ocrevus + EU-Ocrevus	Celltrion	Phase 3	77
LY2127399 + Placebo	Eli Lilly	Phase 2	52
BIIB019 (Daclizumab High Yield Process) + Placebo	AbbVie	Phase 2	52
Daclizumab	AbbVie	Phase 3	77
BIIB019 (Daclizumab High Yield Process) + Placebo	AbbVie	Phase 2	52
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccine	AbbVie	Phase 2	52
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process Placebo	AbbVie	Phase 3	77
Rebif (Interferon beta-1a)	Merck	Pre-clinical	23
Interferon beta-1a	Merck	Pre-clinical	23
Rebif® + Avonex®	Merck	Phase 3	77
Rebif® + Rebif®	Merck	Approved	85
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) alone	Merck	Phase 2	52
Placebo + IFN beta-1a + Methylprednisolone	Merck	Phase 2	52
Interferon beta-1a (Rebif)	Merck	Approved	85
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched Placebo	Merck	Phase 3	77
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched Placebo	Merck	Phase 3	77
Interferon beta 1a	Merck	Pre-clinical	23
Cladribine 10 mg oral tablet	Merck	Approved	85
Evobrutinib + Evobrutinib + Evobrutinib + Placebo + Tecfidera	Merck	Phase 2	52
Minocycline + Placebo	Merck	Phase 2	52

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved

CREONApproved

Venetoclax + AzacitidineApproved

Oxybutynin + PlaceboApproved

Glecaprevir-pibrentasvirApproved